Conversion of Notes and Allotment of Shares

Iconic Labs

23/02/2026 07:00

RNS Number : 8995T

Iconic Labs PLC

23 February 2026

 

Iconic Labs PLC

 

("Iconic" or the "Company")

 

Conversion of Notes and Allotment of Shares

Iconic Labs PLC (LSE:ICON), announces that it has received a valid Conversion Notice.

The Conversion Notice was dated 20 February 2026 and provides for 20 Convertible Notes to be converted into 1,269,841 ordinary shares of £0.0001 in the Company ("Ordinary Shares") at a conversion price of GBP 0.01575 at the aggregate principal amount of £20,000.

Application is therefore being made for an aggregate of 1,269,841 new Ordinary Shares to be admitted to trading on the Main Market of the London Stock Exchange which is expected to be on or around 26 February 2026. These shares rank pari passu with the existing Ordinary Shares of the Company.

Following the issue of these shares, the Company's issued ordinary share capital shall consist of 15,153,868 Ordinary Shares. The figure of 15,153,868 represents the total voting rights in the Company and should be used by shareholders as the denominator for the calculation by which they can determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance & Transparency Rules.

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

 

For any further information or enquiries please contact:

 

Iconic Labs
John Farquharson, Chief Executive Officer
via Yellow Jersey PR
AlbR Capital Limited
David Coffman / Daniel Harris
Tel: +44 (0) 20 7469 0930
Yellow Jersey PR
Charles Goodwin
Annabelle Wills
Tel: +44 (0) 20 3004 9512
iconic@yellowjerseypr.com

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
CONPPUQCPUPQGQU